SCHEMBL2080992

SCHEMBL2080992

CCOC(=O)CC[C@H]1CC[C@H](O)CN1C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.38
USP2 O75604 1/20 0.38
ALOX15 P16050 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CYP2D6 P10635 1/20 0.33
CYP2C19 P33261 1/20 0.33
HIF1A Q16665 1/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
TSHR P16473 1/20 0.33
CYP1A2 P05177 1/20 0.33
SMYD3 Q9H7B4 1/20 0.33
KMT2A Q03164 1/20 0.32
MGAM O43451 1/20 0.32
GAA P10253 1/20 0.32
SI P14410 1/20 0.32
MGAM2 Q2M2H8 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.31
RAB9A P51151 1/20 0.31
PPM1B O75688 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2080986 1.00 ALDH1A1 (0.38) ALDH1A1USP2ALOX15TDP1CYP2D6
SCHEMBL2080989 1.00 ALDH1A1 (0.38) ALDH1A1USP2ALOX15TDP1CYP2D6
SCHEMBL2080273 0.87 ALDH1A1 (0.36) ALDH1A1USP2ALOX15TDP1CYP2D6
SCHEMBL4598122 0.87 ALDH1A1 (0.36) ALDH1A1USP2ALOX15TDP1CYP2D6
SCHEMBL2080551 0.84 SMYD3 (0.43) ALDH1A1USP2ALOX15TDP1LMNA
SCHEMBL2080549 0.84 SMYD3 (0.43) ALDH1A1USP2ALOX15TDP1LMNA
SCHEMBL2080553 0.84 SMYD3 (0.43) ALDH1A1USP2ALOX15TDP1LMNA
SCHEMBL2079460 0.83 CHRM2 (0.37) ALDH1A1USP2ALOX15TDP1CYP2D6
SCHEMBL2080381 0.83 ALDH1A1 (0.34) ALDH1A1USP2ALOX15TDP1CYP2C19
SCHEMBL2079458 0.83 CHRM2 (0.37) ALDH1A1USP2ALOX15TDP1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7906532-B2 Antiserotonine agents; gastrointestinal disorders; irritable bowel syndrome; central nervous system disorders; Alzheimer's disease; cognition activators; analgesics; cardiovascular disorders; antidiabetic agents; sleep disorders PFIZER INC. (US) 2011-03-15 US disclosed
EP-1910340-B1 INDAZOLECARBOXAMIDE DERIVATIVES AS 5HT4 RECEPTOR AGONISTS PFIZER (US) 2009-11-18 EP disclosed
US-20080269211-A1 Indazole Derivatives PFIZER INC 2008-10-30 US disclosed
EP-1910340-A1 INDAZOLECARBOXAMIDE DERIVATIVES AS 5HT4 RECEPTOR AGONISTS Pfizer, Inc. (US) 2008-04-16 EP disclosed
WO-2007010390-A1 INDAZOLECARBOXAMIDE DERIVATIVES AS 5HT4 RECEPTOR AGONISTS PFIZER JAPAN INC. (JP) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269211-A1 Indazole Derivatives GPR119, HRH4, HTR4 ALDH1A1 1475/4885USP2 4524/4885ALOX15 588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.